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Epstein–Barr virus (EBV) is a gammaherpesvirus linked to a number of lymphoid and
epithelial malignancies, including Burkitt lymphoma (BL) in which its frequency ranges
from 30% in sporadic cases to 100% in the endemic ones. The possible contribution
of EBV to BL pathogenesis is largely unknown. It has been suggested that EBV may
be associated with all of the cases, including those diagnosed as EBV negative by
a mechanism of hit-and-run. Early during oncogenesis, viral genes are essential for
initiating disease. Progressively, viral genome is lost to escape the immune system and
host mutations accumulate in proto-oncogenic cell. The main problem with the hit-and-
run hypothesis is the lack of evidence in primary tumors. The routine methods applied
to detect the virus [i.e., immunohistochemistry and EBV-encoded RNAs (EBER) in situ
hybridization (ISH)] have a low specificity and accuracy. The aim of this study was to
identify the most suitable method to detect EBV infection in pathology samples by
applying conventional and non-conventional methods (i.e., EBV-microRNAs detection
and EBV viral load measurement). We investigated a total of 10 cases and we found that
all the samples (n= 6) diagnosed as EBV negative by immunohistochemistry and EBER-
ISH demonstrated the presence of EBV-microRNAs and EBV genome. This points at the
possibility that EBV might have contributed to lymphomagenesis in all our patients, and
propose microRNAs detection as the most specific and sensitive tool to recognize EBV
vestiges. It is worth noting that our data would have considerable implications for EBV-
related diseases control. By using anti-EBV vaccines, one could potentially prevent also
some cancers less suspected of a viral origin because of viral genome loss.
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INTRODUCTION
Epstein–Barr virus (EBV) is a gammaherpesvirus that persistently
infects over 90% of adults, usually without consequence (Queen
et al., 2013). However, EBV is linked to a diverse array
of lymphoid and epithelial malignancies, including Burkitt
lymphoma (BL) (Queen et al., 2013). The virus is detected in 30%
of sporadic BL (sBL), 50% of immunodeficiency associated BL
(ID-BL) and virtually all endemic BL (eBL) (Leoncini et al., 2008).
The possible contribution of EBV to BL pathogenesis is largely
unknown and it is unclear how directly infection and disease are
linked (Rochford et al., 2005). In fact, viral genes seem mostly
to have triggering or accessory roles in disease, and are likely
to be essential for cancer-cell survival only in the early phase
of the neoplastic transformation in non-immunocompromised
carriers (Vereide and Sugden, 2010). Moreover, the role of EBV
is further confounded by the less than total association of the
virus with histologically similar tumors. This may be explained by
the hit-and-run hypothesis for viral-induced lymphomagenesis
which proposes that after eliciting a heritable change in the
gene-expression pattern of the host cell, the genome of tumor
viruses may be completely lost (Ambinder, 2000; Minarovits
et al., 2011). Following, cancers accumulate vast numbers of
host mutations which become the main drivers of oncogenesis,
promoting autonomous growth (Minarovits et al., 2011). Thus,
it seems inevitable that a cancer, with time, will evolve to be
independent from viral gene functions, allowing viral genome
loss. This results in an inverse correlation between the number
of viral genes expressed in these tumor cells and their associated
cellular mutations (Rochford et al., 2005) as it has been recently
demonstrated in cell lines and tumor samples (Abate et al., 2015).
The main problem with the hit-and-run hypothesis has been
lack of evidence in primary tumors; in addition, the studies
present in the literature on the role of EBV in tumorigenesis
have analyzed mainly EBV-positive cancers. Focusing on virus-
positive cancers provide little information about genome loss,
and the difficulty of analyzing spontaneous cancers, where the
molecular changes driving transformation are almost always
unknown, makes firm functional conclusions hard to draw
(Stevenson et al., 2010).
To assess the presence of the virus in a specific sample,
different approaches can be used, most of which are characterized
by a high sensitivity. To date, the most employed methods
for diagnostic purposes are immunohistochemistry and in situ
hybridization (ISH) for EBV-encoded RNAs (EBER). However,
they have a low specificity, and the accuracy of such assays
has been recently called into question by molecular studies that
showed the presence of the virus in samples previously diagnosed
as EBER negative (Gallagher et al., 2003; Qi et al., 2013). More
recently, microRNA (miRNA) expression has been shown to be
a quite sensitive and specific tool to characterize normal and
neoplastic cells, even for pathogens detection (Ma et al., 2016).
By miRNA profiling we recently observed the expression of
EBV-encoded miRNAs in one EBER-negative BL case (Abate
et al., 2015; Piccaluga et al., 2016). Based on that, the aim of
the present study was to identify the most suitable method
to detect EBV infection in pathology samples by comparing
different conventional (immunohistochemistry and EBER-ISH)
and non-conventional (EBV-microRNAs detection and EBV viral
load measurement) methods. We looked for EBV infection
in 10 typical BL cases. Immunohistochemistry and EBER-ISH
failed to identify the virus in six samples, whereas microRNAs
expression profiling, quantitative reverse transcription PCR and
viral load measurement identified a previous EBV exposure in
all the specimens, also in those diagnosed as EBV negative
by conventional tools. Our findings shed new light on the
pathogenesis of EBV-related tumors, highlighting the role of
the virus also in “EBV-negative” cases and proposing EBV-
miRNAs searching as the most sensitive approach to identify also
EBV vestiges. Because of the limitation of using EBV-miRNAs
detection routinely, there is a lack of data to determine the
true burden of EBV-associated cancers worldwide, and the data
available is likely to under represent the epidemiology of EBV
infection. Assessing that EBV might be responsible of a larger
number of cancers than previously known may open the way for
the opportunity of a large scale prevention tactic.
MATERIALS AND METHODS
Patients
The cases cohort was represented by 10 formalin-fixed and
paraffin-embedded (FFPE) samples, retrieved by the Archives
of Siena University Hospital, and characterized by clinic,
morphology, immunohenotype and cytogenetic consistent with
the World Health Organization diagnosis of BL. The mean
age at diagnosis was 14.2 years (range: 3–41 years) with a
male to females ratio of 5:5. The sites of involvement were:
small intestine (n = 4), lymph node (n = 2), head and neck
(n = 1), ovary (n = 1), stomach (n = 1), uterus (n = 1).
None of the patient had underlying immunosuppression. All
individuals were positive for IgG antibodies against viral capsid
antigen (VCA) and EBV nuclear antigen (EBNA), whereas they
were negative for IgM antibodies against VCA and early
antigen (EA).
Immunohistochemistry and EBER-ISH
Immunohistochemical stainings were performed on all cases by
an automated staining system (Ventana BenchMark ULTRA,
Roche diagnostic, Monza-Italy) on FFPE 4 µm-thick sections
with appropriate positive and negative controls included in
each staining run. No epitope retrieval was exploited. UltraView
Universal Detection Kit (Ventana) using HRP multimer and DAB
(as chromogen) was employed. Each case was scored as positive
or negative for EBNA-1 (Santa Cruz, Heidelberg, Germany). ISH
for EBER was carried out in each sample on 5µm-thick section as
previously described (Abate et al., 2015). A control slide, prepared
from a paraffin-embedded tissue block containing metastatic
nasopharyngeal carcinoma in a lymph node accompanied each
hybridization run.
Laser Capture Microdissection
The neoplastic population of each sample was isolated from
haematoxylin and eosin stain sections using immuno-guided
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FIGURE 1 | Immunohistochemical and in situ hybridization findings. (A) EBER-positive case is depicted; (B) EBER-negative specimens are shown. Original
magnification: 25X.
laser capture microdissection to avoid the risk of including
reactive lymphocytes that might alter our findings in the
following analysis [i.e., quantitative reverse transcription PCR (q-
PCR) and miRNA profiling]. Sections were microdissected using
a PixCell IIe microscope (Arcturus Engineering, MGW, Florence,
Italy) as previously described (Ambrosio et al., 2015a).
microRNAs Profiling
Total RNA was extracted from FFPE sections of nine primary
tumors using the FFPE miRNA Easy kit (Qiagen, Valencia,
CA, USA), according to the manufacturer’s instructions. Small
RNA libraries were prepared from 1 mg of a high-quality
RNA (RNA Integrity Number ≥ 8) with the TruSeq Small
RNA kit (Illumina). 1 × 36 sequencing was performed on the
Illumina MiSeq platform. Thirty-six bp length raw sequences
were demultiplexed using the Illumina pipeline CASAVA
v1.8. A quality check of the run experiment was performed
by FastQC1. Low quality reads and adapter sequences were
trimmed off using Trimmomatic (Bolger et al., 2014). The
high quality reads, with a length of 17–36 bp were clipped
and subsequently aligned to the latest miRBase release (v 21
July 2014) (Kozomara and Griffiths-Jones, 2014) by Novoalign2.
miRNA expression profiles were built by calculating the sum
of read counts for each miRNA, according to the alignment
criteria. Variance-stabilizing transformed count data were used
to build a Euclidean distance matrix, followed by hierarchical
clustering analysis to study the intra-samples correlations.
miRNA differential expression analysis was performed using
Bioconductor’s package DESeq (Anders and Huber, 2010). The
1http://www.bioinformatics.babraham.ac.uk/projects/fastqc
2http://www.novocraft.com
obtained read counts for each identified miRNA were first
normalized by scaling for library size factors in order to deal
with variation among samples. The differential expression values
were estimated using a negative binomial distribution model
and local regression to estimate the relationship between the
dispersion and the mean of each miRNA. Raw values were
considered as statistically significant when p-value < 0.05.
Heatmap of normalized count table and principal component
analysis were performed by R. Following alignment and
normalization (see above), the data was further analyzed
using GeneSpring GX12 as previously described (Navari et al.,
2015).
Quantitative Reverse Transcription PCR
Assay to Confirm and Quantify the
Presence of Viral miRNAs
Taqman primers and probes specific for each selected viral
miRNA were applied to analyse by q-PCR all cases. Total RNA
was extracted using miRNAeasy FFPE kit (Qiagen, Valencia, CA,
USA) according to the manufacturer’s instructions. Three T-LLs
samples, currently considered not to be affected by EBV were
used as negative control. RNU6B was used as endogenous control
(Applied Viosystems, Applera, Italy) and the absolute expression
was calculated using the 2−1ct formula. Kruskal–Wallis Test was
applied for statistical analysis.
Quantitative Reverse Transcription PCR
Assay to Quantify EBV Genome Load
To further strengthen our findings and prove the presence of
EBV also in EBER negative samples, viral load measurement
was carried out. DNA was extracted from FFPE tissue using
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FIGURE 2 | microRNA expression profiling results and reverse transcription validation. (A) Normalized intensity expression values of EBV-encoded miRNA
in Burkitt lymphoma cases; expression values of all EBV-encoded miRNA are plotted for each case and are represented by boxes; bars indicate the mean values.
(B) Unsupervised hierarchical clustering of Burkitt lymphoma cases based on the expression of EBV encoded miRNAs; the dendrogram was generated using a
hierarchical clustering algorithm based on the average-linkage method. In the matrix, each column represents a sample and each row represents a miRNA. The color
scale bar shows the relative miRNA expression changes normalized by the standard deviation (0 is the mean expression level of a given gene). (C) Unsupervised
hierarchical clustering of EBER-negative Burkitt lymphoma cases based on the expression of EBV-encoded miRNAs; The dendrogram was generated using a
hierarchical clustering algorithm based on the average-linkage method. In the matrix, each column represents a sample and each row represents a miRNA. The color
scale bar shows the relative miRNA expression changes normalized by the standard deviation (0 is the mean expression level of a given gene). (D) Differential
expression of EBV-encoded miRNAs in EBER-negative and EBER-positive Burkitt lymphomas versus control samples (lymphoblastic lymphoma) by q-PCR.
Expression values are reported on the y-axis. Standard error is indicated by bars.
proteinase K digestion and NucleoSpin Kit, according to
the manufacturer’s instructions. Beta globin Human beta 2
microglobulin (B2m) and ApoB genes were used as a control for
the efficacy of extraction and amplification of DNA from paraffin
embedded tissue. According to the data from the literaturate
(Junying et al., 2003) a standard curve was generated using 10-
fold dilutions of Namalwa DNA varying from 500,000 to 0,5
copies of EBV DNA, assuming that Namalwa cell line is diploid
and carry two copies of EBV per cell, equivalent to 3 × 105
copies of EBV/µg DNA. All cases were screened by q-PCR
targeting BamH1 W and EBNA-1 conserved region of EBV
genome. BamH1 W targets a reiterated sequence that is present
at approximately 10 copies per EBV genome and it appears to be
the most sensitive method to prove the presence of viral genome,
detecting low level virus. EBNA-1 targets a single copy highly
conserved gene and is essential for maintaining the virus long
term in dividing cells. Amplification reactions were performed
in 50 µl volumes as previously described (Junying et al., 2003).
Each experiment included DNA samples prepared from EBER-
positive and EBER-negative cases, as well as water-only controls.
Samples were considered negative if exceeded 40 cycles. The
quantification results for experimental samples were extrapolated
from the EBNA-1 and BAMH1 W calibration curve (Junying
et al., 2003).
RESULTS
Immunohistochemistry and In situ
Hybridization Findings
We screened all our samples (n = 10) for EBV infection by
performing immunohistochemistry and EBER-ISH to identify
the presence of EBV-related products. Four out of 10 cases
showed the typical nuclear positivity for EBNA-1 staining in
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FIGURE 3 | Detection of EBV genome by reverse transcription assay. Serial dilution of Namalwa DNA containing 500,000 to 0,5 copies of EBV genomes were
amplified using primer/probe combination specific for EBV EBNA-1 (A) and BamH1 W conserved region (B). The y-intercept corresponds to the number of cycles.
The x-intercept corresponds to the copy number of each target expressed in log 10 scale.
almost all the neoplastic cells. By applying ISH for EBV, we
observed that only four samples retained the EBV-encoded RNAs,
as demonstrated by the black signal revealed in the nucleus of
about 70–95% of neoplastic cells (Figure 1A). Six cases were
negative for EBNA-1 and ISH for EBER (Figure 1B). In these
cases no stain was detectable neither in the neoplastic cells nor
in reactive small lymphocytes.
microRNAs Expression Profiling Results
and Quantitative Reverse Transcription
PCR Validation
EBER-positive BL samples showed a clear expression of viral
miRNAs but also all EBER-negative cases presented some
degree of expression of at least one EBV-miRNA (Figure 2A).
Specifically, in two cases we found four different miRNAs, in
four cases we detected 2, 3, 9, and 17 miRNAs, respectively. In
total, 19 different virus-encoded miRNAs were revealed. Some of
them were consistently expressed in more than two samples, such
as ebv-miR-BART10-3p (n = 4), ebv-miR-BART9-5p (n = 4),
ebv-miR-BART19-3p (n = 3), ebv-miR-BART8-5p (n = 3).
Consistently, when unsupervised hierarchical clustering of BL
cases based on the expression of EBV-miRNAs was performed,
EBER-negative and EBER-positive groups were clearly distinct;
again, some degree of miRNA expression in EBER-negative
cases was observed (Figure 2B). When EBER-negative BL cases
were clustered alone, differences among samples were more
evident with a clearly variable expression of virus encoded
miRNAs (Figure 2C). To validate miRNA profiling results,
q-PCR analysis was employed and demonstrated a significant
differential expression for all the tested miRNAs, namely ebv-
miR-BART9-5p (p = 0.006), ebv-miR-BART10-3p (p = 0.002),
and ebv-miR-BART19-3p (p = 0.004), viral miRNAs being
expressed in all 10 BL samples but not in T-LL specimens
(Figure 2D).
EBV Viral Load Measurement
The quantification results were extrapolated from the EBNA-1
and BAMH1 W calibration curve where the linear relationship
(R2) reached 0.998. The EBV genome was detected in 6/6 cases
and all these samples contained low copy numbers of the EBV
genomes, ranging of 2.07–21.03 copies/1000 cells per EBNA-1
and 1.23–15.28 copies/1000 cells per BAMH1 W (Figures 3A,B).
Otherwise, Q-PCR analysis of EBER-positive cases revealed much
higher viral loads (more than 25,000 copies/1000 cells per EBNA1
and 15,000 copies/1000 cells per BAMH1 W). EBV was regularly
detectable in microdissected tumor cells from EBV-positive
NPC controls while EBV was not detectable in T-LL negative
controls.
Frontiers in Microbiology | www.frontiersin.org 5 March 2017 | Volume 8 | Article 229
fmicb-08-00229 February 27, 2017 Time: 17:29 # 6
Mundo et al. EBV-Encoded miRNAs in EBER-Negative BL cases
DISCUSSION
Epstein–Barr virus is thought to play a causative role in the
pathogenesis of EBV-positive BL. The etiology of cases lacking
its genome in neoplastic cells is poorly understood, but is has
been suggested that EBV may use a hit-and-run mechanism in
them. EBV supplies a normal B-cell information to survive and
grow that are potentially oncogenic (hit). A healthy immune
system removes these proto-tumor cells because they express
recognized viral antigens (Rochford et al., 2005). EBV can avoid
elimination of infected cells by inducing epigenetic alterations
and silencing of targeted viral genes in the host cell (run)
(Queen et al., 2013; Birdwell et al., 2014). These alterations are
stable and heritable and would be maintained also after the
loss of the virus (Queen et al., 2013; Birdwell et al., 2014).
Such ability of EBV to manipulate the host machinery to
silence its own gene expression and to reshuﬄe the cellular
epigenome resulting in long lasting cellular consequences, can
act as a mechanistic framework for the hit-and- run oncogenesis
(Queen et al., 2013; Birdwell et al., 2014). Accordingly,
selection favors a proto-tumor cell that evolves to reduce its
dependence on the virus from proliferation and survival by
gaining complementary cellular mutations (Ambrosio et al.,
2015b). In more evolved tumors, the only viral genes expressed
are those poorly immunogenic and non-immunogenic (i.e.,
EBER and viral-encoded miRNAs). Unfortunately the standard
methods to detect EBV often fail to identify also these non-
immunogenic molecules, but if the virus is truly responsible
for all BL, all cases should theoretically show some evidence of
the infection (Queen et al., 2013). Therefore, the challenge is
to devise investigative strategies to prove or exclude hit-and-run
oncogenesis (Ambinder, 2000).
In our study we investigated this possibility by applying
conventional and non-conventional tools on a series of BL cases.
In fact, the main problems with the hit-and-run hypothesis
are the absence of proof in natural setting that led to track
the fate of an infected cell, and the lack of evidence in
primary tumors (Stevenson et al., 2010). The only data we
have concerns in vitro studies. It has been shown that in
some cases of episome loss from BL cell lines in tissue
culture, fragments of the EBV genome are incorporated into
cellular DNA (Srinivas et al., 1998). Furthermore, in a series
of sBL, similar fragments of the EBV genome were found
in tumors that by standard criteria (EBER-ISH or EBNA-
1 immunohistochemistry) would be classed as virus-negative
(Srinivas et al., 1998).
The present study adds new evidence to the existing
literature demonstrating that the routine methods employed to
identify EBV (i.e., immunohistochemistry and EBER-ISH) are
disappointing as we identified EBV genome in cases diagnosed
as EBNA-1 and EBER negative (Gallagher et al., 2003; Stevenson
et al., 2010). We also provide evidence to propose miRNAs
detection as the most specific and sensitive tool to identify even
EBV vestiges (e.g., EBV exosomes) and diagnose a previous
infection in “EBV-negative” patients. According to the hit-and-
run hypothesis, our findings support the possibility that EBV
might have contributed to lymphomagenesis in our samples by
initiating the oncogenic process. Then EBV genome was lost
at each cell cycle and no longer detectable by conventional
methods, being the tumor under the selective pressure exerted
by the immune system. In fact, every population of proliferating
EBV-positive cells loses 8% of the viral genomes each cell cycle;
after eight cycles, only 50% of the viral DNA will remain;
after 50 cycles, only 1% will persist in the population (Vereide
and Sugden, 2009, 2010). The few remaining EBV genome in
neoplastic cells would then be responsible for the production of
the detected miRNAs. In this regard, selective release and transfer
of RNA via exosomes might play a relevant role as recently
demonstrated in other settings (Baglio et al., 2016). Though our
findings do not represent a definitive proof of the presence of
EBV inside the neoplastic cells, they highlight for the first time
the possibility that EBV might contribute to the development
of more cancers than simply those remaining viral genome-
positive. In fact, the virus may impact on host cell homeostasis
in various ways by interfering with cellular miRNAs expression
and by encoding its own genes and miRNAs (Lenze et al., 2011).
EBV-miRNAs may compete with miRNAs machinery and target
cellular genes, thus dysregulating key pathways.
Whether confirmed on a larger cohort of cases and different
tumor types, the current study may further support the
rationale for strengthening the effort toward EBV vaccines that
could potentially prevent the development of EBV-associated
neoplasms independently of the presence or absence of viral
genomes in the neoplastic cells, thus affecting the worldwide
epidemiology of lymphomas. This is an idea worth considering,
and seems to be realistic, because it has been demonstrated that
vaccinia against EBV superficial antigens could protect from or
delay EBV infection in infants (Stevenson et al., 2010).
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